April 10, 2023

Medullary thyroid cancer (MTC) is a rare cancer, generally diagnosed at early stages of the disease when prognosis is favorable. Mutations in the RET gene are involved in the development of the cancer and are common in patients with MTC. 

February 27, 2023

Acromegaly Symptom Diary  Acromegaly is a rare but serious condition caused by pituitary tumors that result in overabundance of growth hormone and insulin-like growth factor-1. This hormonal excess results in tissue growth, including changes to facial features.

February 27, 2023

Non-small cell lung cancer (NSCLC) is an aggressive disease, with poor prognosis and a high likelihood of brain metastases. Overall survival rates for patients with NSCLC with brain metastases are low.

February 6, 2023

Traumatic brain injury (TBI) is an alteration in brain function caused by an external force. TBI of so-called mild severity (mTBI) represents 70-90% of cases and is a frequent cause of emergency department visits.

January 19, 2023

Photo from left to right: Alison Kawai, Mary Anthony, RTI International President and CEO, Tim Gabel, Bradley

January 9, 2023

Research coauthored by RTI Health Solutions researchers will be presented at the 2023 Respiratory Synctial Virus Foundation. Projected impact of RSV vaccine in US adults ≥ 60 years of age. Krishnarajah G, Talbird S, Cook C, DeMartino J, Hernandez-Pastor L. Poster 

September 22, 2022

Josephine (Jo) Mauskopf, PhD, MHA, Vice President of Health Economics at RTI Health Solutions, has been appointed as a Distinguished Fellow at RTI International.

September 9, 2022

New Research on the Public Health and Economic Benefits of Pediatric Immunization in the US Two studies just published in Pediatrics give us an updated picture of how well childhood immunizations prevent disease and the economic impact of this disease prevention.

August 16, 2022

Christine Barnett, PhD, Associate Director of Health Economics at RTI Health Solutions, proudly announces publication of Artificial Intelligence for Healthcare: Interdisciplinary Partnerships for Analytics-Driven Improvements in a Post-

August 4, 2022

RTI International, parent

July 21, 2022

Top-scorers demonstrated commitment to disability inclusion and equality RTI International, a nonprofit research institute and parent company of RTI Health Solutions, has

June 29, 2022

Despite recent advances in the treatment of psoriatic arthritis (PsA), for some who live with the condition, available treatments do not supply adequate relief for their most troublesome symptoms. To help improve lives, new treatments need to address these unmet needs.

June 8, 2022

Learn more about the award-winning presentation along with our full list of RTI-HS contributions to ISPOR 2022.

May 27, 2022

One of the cultural pillars at RTI Health Solutions (RTI-HS) is respect for the individual. Throughout the organization, colleagues work to show respect toward others and hold themselves accountable to this principle. 

May 18, 2022

Bradley, who has been a member of ISPE since 2011, was recommended for this honor by a committee of his peers

May 5, 2022

RTI-HS has a rich history of contributing to ISPE’s mission

March 15, 2022

The recognition honors companies demonstrating exceptional leadership and a commitment to business integrity through best-in-class ethics, compliance, and governance practices 

March 1, 2022

Guidance Expanded to Reflect Developments in Reporting Economic Evaluations of Health Interventions

February 12, 2022

Most of what we know about treatments, adverse events, and the overall survival of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) comes from clinical trials. However, confirmatory real-world evidence, especially in the Medicare population, is limited.

January 27, 2022

Kenneth J. Rothman, DrPH, formerly Vice President of Epidemiology Research at RTI Health Solutions, has transitioned to Distinguished Fellow Emeritus after 16 years with RTI-Health Solutions.

November 11, 2021

RTI-HS is collaborating with the FDA to ensure that rigorous, valid methods are used to evaluate COVID-19 vaccine effectiveness in the real world.